Itolizumab, new drug for COVID-19 patients to cost Rs 8,000 per vial

Biotechnology major Biocon on Monday said it will launch biologic drug Itolizumab for the treatment of moderate to severe COVID-19 patients at a price of around 8,000 per vial.   The company......

Sales of Biocon's itolizumab surge as phase-4 clinical trials begin

In India, itolizumab, known by the brand name Alzumab, has been priced at Rs 8,000 per vial. Most patients require four vials for Covid-19 treatment, taking the cost of the therapy to Rs 32,000.......